Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flurbiprofen axetil (5ffb84)
- Development stage
- Approved
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Flurbiprofen axetil is a prodrug of flurbiprofen, a non-steroidal anti-inflammatory drug (NSAID). It is formulated with lipid microspheres to enhance its targeting and bioavailability. Upon administration, flurbiprofen axetil is rapidly hydrolyzed by carboxylesterase in the body to its active metabolite, flurbiprofen. Flurbiprofen then exerts its therapeutic effects by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins, which are key mediators of pain, inflammation, and fever. This mechanism provides potent analgesic, antipyretic, and anti-inflammatory actions.
- Other names
- fluorine noir phenolic ester氟比洛芬酯
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Flurbiprofen axetil (5ffb84).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flurbiprofen axetil (5ffb84).